CAM Research Should Test For Adverse Interactions – Toxicologist
This article was originally published in The Tan Sheet
Executive Summary
Future research on complementary and alternative medicine should include clinical testing on interactions between dietary supplements and conventional medications, according to one toxicology expert
You may also be interested in...
NCCAM turns five
National Center for Complementary & Alternative Medicine celebrates its fifth anniversary by announcing the launch of its second five-year strategic plan, NIH center says during recent advisory council meeting. Draft of the plan will be released in the fall. NCCAM director Stephen Straus, MD, cites the center's research portfolio containing "over 300 projects" and including the "largest ever placebo-controlled clinical trials of popular dietary supplements like glucosamine for degenerative arthritis and ginkgo biloba for dementia" among NCCAM's noteworthy accomplishments. Straus also notes that "most importantly, a body of data is emerging from NCCAM's investments in research that is informing public policy and helping guide practices"...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands